NCAM1 and neoplasm: Zhang et al. [27] also noted the enhancements in tumor-infiltrating lymphocyte counts, with significant increases in the CD16 (MD = 0.04, 95% CI [0.02–0.06], p < 0.001) and the CD56 levels (MD = 0.05, 95% CI [0.03–0.06], p < 0.001).